215 related articles for article (PubMed ID: 30713089)
1. Evidence Synthesis to Accelerate and Improve the Evaluation of Therapies for Metastatic Hormone-sensitive Prostate Cancer.
Tierney JF; Vale CL; Parelukar WR; Rydzewska L; Halabi S
Eur Urol Focus; 2019 Mar; 5(2):137-143. PubMed ID: 30713089
[TBL] [Abstract][Full Text] [Related]
2. Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis.
Rydzewska LHM; Burdett S; Vale CL; Clarke NW; Fizazi K; Kheoh T; Mason MD; Miladinovic B; James ND; Parmar MKB; Spears MR; Sweeney CJ; Sydes MR; Tran N; Tierney JF;
Eur J Cancer; 2017 Oct; 84():88-101. PubMed ID: 28800492
[TBL] [Abstract][Full Text] [Related]
3. The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation.
McNamara M; Sweeney C; Antonarakis ES; Armstrong AJ
Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):306-318. PubMed ID: 29263421
[TBL] [Abstract][Full Text] [Related]
4. Comparative Effectiveness of All Available Treatments for Metastatic Hormone-Sensitive Prostate Cancer: A Network Meta-analysis.
Mansourian M; Ghasemi Ms K; Khorsandi PhD D; Vaseghi G
Am J Ther; 2020; 27(5):e541-e543. PubMed ID: 31107252
[No Abstract] [Full Text] [Related]
5. Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.
Damodaran S; Lang JM; Jarrard DF
J Urol; 2019 May; 201(5):876-885. PubMed ID: 30747897
[TBL] [Abstract][Full Text] [Related]
6. Novel androgen axis systemic therapies for metastatic hormone-sensitive prostate cancer.
Hahn AW; Hale P; Rathi N; Agarwal N
Curr Opin Urol; 2017 Nov; 27(6):559-565. PubMed ID: 28816716
[TBL] [Abstract][Full Text] [Related]
7. Is There a Benefit of Addition Docetaxel, Abiraterone, Celecoxib, or Zoledronic Acid in Initial Treatments for Patients Older Than 70 Years With Hormone-sensitive Advanced Prostate Cancer? A Meta-analysis.
Landre T; Guetz GD; Chouahnia K; Fossey-Diaz V; Taleb C; Culine S
Clin Genitourin Cancer; 2019 Aug; 17(4):e806-e813. PubMed ID: 31227430
[TBL] [Abstract][Full Text] [Related]
8. Are There Still Patients with Metastatic Hormone-sensitive Prostate Cancer Who Should Be Treated with Androgen Deprivation Monotherapy?
Kretschmer A; Todenhöfer T
Eur Urol Focus; 2019 Mar; 5(2):114-116. PubMed ID: 30482584
[TBL] [Abstract][Full Text] [Related]
9. Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis.
Tucci M; Bertaglia V; Vignani F; Buttigliero C; Fiori C; Porpiglia F; Scagliotti GV; Di Maio M
Eur Urol; 2016 Apr; 69(4):563-573. PubMed ID: 26422676
[TBL] [Abstract][Full Text] [Related]
10. Impact of next-generation hormonal agents on treatment patterns among patients with metastatic hormone-sensitive prostate cancer: a real-world study from the United States, five European countries and Japan.
Leith A; Ribbands A; Kim J; Clayton E; Gillespie-Akar L; Yang L; Ghate SR
BMC Urol; 2022 Mar; 22(1):33. PubMed ID: 35277153
[TBL] [Abstract][Full Text] [Related]
11. Qualitative and Quantitative Assessment of Patient and Carer Experience of Chemotherapy (Docetaxel) in Combination with Androgen Deprivation Therapy (ADT) for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC).
Ito T; Grant L; Duckham BR; Ribbands AJ; Gater A
Adv Ther; 2018 Dec; 35(12):2186-2200. PubMed ID: 30415297
[TBL] [Abstract][Full Text] [Related]
12. Management of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): an Evolving Treatment Paradigm.
Weiner AB; Nettey OS; Morgans AK
Curr Treat Options Oncol; 2019 Jul; 20(9):69. PubMed ID: 31286275
[TBL] [Abstract][Full Text] [Related]
13. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data.
Vale CL; Burdett S; Rydzewska LHM; Albiges L; Clarke NW; Fisher D; Fizazi K; Gravis G; James ND; Mason MD; Parmar MKB; Sweeney CJ; Sydes MR; Tombal B; Tierney JF;
Lancet Oncol; 2016 Feb; 17(2):243-256. PubMed ID: 26718929
[TBL] [Abstract][Full Text] [Related]
14. Appendix 1: Cancer of the Prostate: eUpdate published online 28 September 2017 (http://www.esmo.org/Guidelines/Genitourinary-Cancers/Cancer-of-the-Prostate).
ESMO Guidelines Committee
Ann Oncol; 2018 Oct; 29(Suppl 4):iv256. PubMed ID: 30285212
[No Abstract] [Full Text] [Related]
15. Contemporary Management of the Newly Diagnosed Prostate Cancer Patient with Metastatic Disease at Presentation.
Xu L; Pachynski RK
Curr Urol Rep; 2018 Aug; 19(10):79. PubMed ID: 30105573
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy for hormone-refractory prostate cancer.
Shelley M; Harrison C; Coles B; Staffurth J; Wilt TJ; Mason MD
Cochrane Database Syst Rev; 2006 Oct; (4):CD005247. PubMed ID: 17054249
[TBL] [Abstract][Full Text] [Related]
17. Phase 3 randomized trial evaluating second-line hormonal therapy versus docetaxel-estramustine combination chemotherapy on progression-free survival in asymptomatic patients with a rising prostate-specific antigen level after hormonal therapy for prostate cancer: an Eastern Cooperative Oncology Group (E1899), Intergroup/Clinical Trials Support Unit study.
Walczak JR; Carducci MA;
Urology; 2003 Dec; 62 Suppl 1():141-6. PubMed ID: 14747052
[TBL] [Abstract][Full Text] [Related]
18. SYSTEMIC TRIPLE THERAPY IN METASTATIC HORMONE SENSITIVE PROSTATE CANCER (MHSPC).
Omrčen T
Acta Clin Croat; 2022 Oct; 61(Suppl 3):81-85. PubMed ID: 36938560
[TBL] [Abstract][Full Text] [Related]
19. Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis.
Burdett S; Boevé LM; Ingleby FC; Fisher DJ; Rydzewska LH; Vale CL; van Andel G; Clarke NW; Hulshof MC; James ND; Parker CC; Parmar MK; Sweeney CJ; Sydes MR; Tombal B; Verhagen PC; Tierney JF;
Eur Urol; 2019 Jul; 76(1):115-124. PubMed ID: 30826218
[TBL] [Abstract][Full Text] [Related]
20. Treatment of hormone-naïve metastatic prostate cancer.
Hamilou Z; Saad F; Fizazi K
Curr Opin Support Palliat Care; 2018 Sep; 12(3):334-338. PubMed ID: 30015691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
